The FDA first approved upadacitinib on August 16, 2019, for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate or other similar medications.

The U.S. Food and Drug Administration (FDA) granted approval for Fedratinib on August 16, 2019.

The U.S. Food and Drug Administration (FDA) granted approval for Pretomanid on August 14, 2019.

The U.S. Food and Drug Administration (FDA) approved Pexidartinib on August 2, 2019.

The U.S. Food and Drug Administration (FDA) approved Darolutamide, marketed under the brand name Nubeqa, on July 30, 2019.

The U.S. Food and Drug Administration (FDA) approved Recarbrio, which is a combination of imipenem, cilastatin, and relebactam, on July 16, 2019.

The U.S. Food and Drug Administration (FDA) approved amlodipine, which is marketed under brand names such as Norvasc, Katerzia, and Norliqva, for medical use. This approval was granted on July 8, 2019.

The U.S. Food and Drug Administration (FDA) granted approval for selinexor on an accelerated basis on July 3, 2019.

bremelanotide, marketed under the brand name Vyleesi, is FDA approved. The FDA granted approval for bremelanotide on June 21, 2019.

Levocetirizine is a small, powerful drug that works as an H1 receptor antagonist to treat various allergies, including respiratory issues, dermatitis, and eczema.

Nortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs.

Valsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs).